TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04006925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Oxybate
Description: Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
Study: NCT01551004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be given to 2 subjects of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be given to 2 subjects of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be given to 2 subjects of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be given to 2 subjects of each cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be given to 2 subjects of each cohort.
Study: NCT01829984

Intervention type: OTHER
Intervention: Verbal and Written Instruction
Description: Pre-teaching Evaluation: Patient~* Pre-teaching Evaluation: Caregiver~  o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~* Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.

Intervention type: OTHER
Intervention: Verbal and Written Plus Simulation
Description: Post-injection Evaluation: Patient~* Post-injection Evaluation: Caregiver~  o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~* Nurse Evaluation: Control~* Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study.
Study: NCT03824366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volumetric MR imaging
Description: This will most frequently be supine with arms positioned so not in the way of treatment beams.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care
Study: NCT01465828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
Study: NCT02955121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescriber Access to Genetic Information
Study: NCT03804775

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum lipid profile
Description: Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum lipid profile
Description: Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
Study: NCT01457235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
Study: NCT03485677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat GZ385660
Description: Pharmaceutical form: Capsule, Liquid~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat GZ385660
Description: Pharmaceutical form: Capsule, Liquid~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiglucerase GZ437843
Description: Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous
Study: NCT02949401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality App
Description: The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
Study: NCT01228422

Intervention type: BIOLOGICAL
Intervention: Interferon alpha 2a
Description: 3MUI

Intervention type: BIOLOGICAL
Intervention: Interferon alpha 2a
Description: 3MUI
Study: NCT03757234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: po tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: po tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: iv solution/po tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: iv solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: iv solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: iv solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: iv solution
Study: NCT02531178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-257
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-257
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-257
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ABBV-257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ABBV-257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ABBV-257
Study: NCT03290612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1.5g Ascorbic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1.5g Ascorbic Acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive placebo to mimic 1.5g ascorbic acid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive placebo to mimic 1.5g ascorbic acid.
Study: NCT02778126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]Prexasertib
Description: Administered IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV Infusion
Study: NCT03410043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04269915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: female Schistosoma mansoni cercariae
Description: Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
Study: NCT03604822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
Study: NCT05839223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped.
Study: NCT01958840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Depression Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Study: NCT01397994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Patients in the control arm would be advised atenolol 50 mg od
Study: NCT03583645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incremental theory of personality
Description: The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
Study: NCT03885466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking exercise
Description: Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
Study: NCT01320423

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Trial
Description: Surgical Trial in Lobar Intracerebral Haemorrhage
Study: NCT02028832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIM consult and service provision
Description: If service is requested, treatment options include acupuncture/acupressure, massage, and reiki

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
Study: NCT01978366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state
Study: NCT03030937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan was used as second line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was used as second line treatment with AGC.
Study: NCT01676948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
Study: NCT04959201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE plus AO
Description: Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
Study: NCT01676948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
Study: NCT03233178

Intervention type: OTHER
Intervention: Non-interventional

Intervention type: OTHER
Intervention: Non-interventional

Intervention type: OTHER
Intervention: Non-interventional

Intervention type: OTHER
Intervention: Non-interventional
Study: NCT04959201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NMDAE plus Placebo Cap
Description: Use of an NMDA enhancer plus placebo as a comparator.
Study: NCT03791502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Method Exercises
Description: Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Method Exercises
Description: Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
Study: NCT00502034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: Interferon Alfa-2a in combination with Interleukin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interferon Alfa-2a in combination with Interleukin
Study: NCT02067234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care/Education
Description: Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation/Coping Prevention
Description: In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
Study: NCT04141735

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: no intervention
Study: NCT02477280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Cross-over

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Cross-over

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Medikinet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medikinet
Study: NCT03253016

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal swab -microbiome test and blood test for cytokines
Description: vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal swab -microbiome test and blood test for cytokines
Description: vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
Study: NCT02281526

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093
Study: NCT00171873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR (Long-acting release)
Description: 30 mg intramuscularly every 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride intramuscularly every 28 days